Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2018 /
Role of chemotherapy in the treatment of metastatic breast cancer patients

4th - 8th Dec 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 10.12.18
Views: 3595

Professors Joseph Gligorov, Yen-Shen Lu, Chris Twelves and Dr Reshma Mahtani

Professors Joseph Gligorov, Yen-Shen Lu, Chris Twelves and Dr Reshma Mahtani meet in San Antonio at the San Antonio Breast Cancer Symposium 2018 annual meeting for an educational breast cancer panel discussion. Their talk covers the role of chemotherapy in the treatment of metastatic breast cancer patients.

Professor Gligorov chairs the discussion, opening by asking Dr Mahtani to comment on recent data surrounding novel chemotherapy combinations used to treat metastatic breast cancer patients, in particular in the triple-negative population. Here Dr Mahtani discusses the combination of eribulin with gemcitabine referencing the data seen at SABCS. Prof Twelves then comments on eribulin’s efficacy as a single agent, and the group discuss the use of eribulin as a backbone regimen in the treatment of mBC patients.

The panel then discuss the importance of individualising dosage in breast cancer patients, and the need for precision medicine and personalised chemotherapy, here referencing BRCA status, SNPs and treating patients with disease recurrence.

The discussion then moves to Prof Lu who comments on the combination of chemotherapy with anti HER2 regimens, and Prof Twelves discusses the phase II and real-world equivalent data.

Prof Gligorov then asks Prof Twelves to comment on the combination of chemotherapy with antiangiogenic agents. Here the panel discuss the use of 2nd line eribulin in combination with bevacizumab following taxane treatment, and the efficacy and toxicity profile of the drug in this setting.

The discussion is summarised by speaking through the role of chemotherapy in the treatment pathway of mBC patients, and the importance of understanding both the safety and efficacy of the chemotherapeutic agent used alongside the individual needs of the patient.

Novel chemotherapy combination regiments
Personalised treatment approaches for breast cancer patients
Chemotherapy and anti-HER2 agents
Chemotherapy and anti-angiogenic agents
Disease control with taxane and eribulin
Treatment strategies in the clinic

This programme has been supported by an unrestricted educational grant from Eisai

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation